David A. Hutton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David A. Hutton has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Vienna E. Brunt
University of Colorado Boulder
9 shared publications - Douglas R. Seals
University of Colorado Boulder
8 shared publications - Zachary Stephen Clayton
University of Colorado Anschutz Medical Campus
8 shared publications - Abigail G. Casso
Department of Integrative Physiology, University of Colorado Boulder, Boulder, Colorado, United States
6 shared publications Nicholas S. VanDongen
University of Colorado Boulder
5 shared publications- Sophia A. Mahoney
Department of Integrative Physiology University of Colorado Boulder Boulder Colorado USA
5 shared publications
Latest Publications
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 329 (6) , H1672-H1683
Cellular senescence mediates doxorubicin chemotherapy-induced vascular endothelial dysfunction: translational evidence of prevention with senolytic treatment
We demonstrate that cellular senescence contributes to doxorubicin-related vascular endothelial dysfunction and establishes efficacy for the use of senolytic therapy to improve vascular function following doxorubicin administration. Mechanistically, we found that cellular senescence reduced NO bioavailability and promoted excessive production of vascular mitochondrial superoxide-related oxidative stress, both of which were prevented with senolytic therapy. We translated these findings to humans and showed that ex vivo exposure to doxorubicin impaired arteriole endothelial function, which was prevented with senolytic exposure.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 329 (6) , H1672-H1683
Cellular senescence mediates doxorubicin chemotherapy-induced vascular endothelial dysfunction: translational evidence of prevention with senolytic treatment
We demonstrate that cellular senescence contributes to doxorubicin-related vascular endothelial dysfunction and establishes efficacy for the use of senolytic therapy to improve vascular function following doxorubicin administration. Mechanistically, we found that cellular senescence reduced NO bioavailability and promoted excessive production of vascular mitochondrial superoxide-related oxidative stress, both of which were prevented with senolytic therapy. We translated these findings to humans and showed that ex vivo exposure to doxorubicin impaired arteriole endothelial function, which was prevented with senolytic exposure.
- 1 October 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (10) , 1767-1777
Cellular Senescence Mediates Doxorubicin Chemotherapy-Induced Aortic Stiffening: Role of Glycation Stress
BACKGROUND: Mechanisms underlying doxorubicin chemotherapy-induced aortic stiffening are incompletely understood. To determine the role of cellular senescence and the senescence-associated secretory phenotype (SASP) in mediating doxorubicin-induced aortic stiffening and the influence of senolytic therapy. METHODS: Aortic stiffness (aortic pulse wave velocity) and associated mechanisms were assessed in young adult p16-3MR mice, a model that allows for genetic-based clearance of senescent cells with ganciclovir. Young (4–6 months) mice were injected with doxorubicin and subsequently treated with ganciclovir or the senolytic ABT263. We evaluated the influence of SASP-associated circulating factors in plasma (the circulating SASP milieu) in mediating aortic stiffening ex vivo (aortic elastic modulus) and examined the contribution of glycation stress. RESULTS: Doxorubicin increased aortic pulse wave velocity (425±6 versus control, 353±5 cm/s; P P P =0.02 versus plasma from control mice), whereas plasma from doxorubicin-ganciclovir and doxorubicin-ABT263 groups did not. Glycation stress was implicated in SASP-mediated aortic stiffening with doxorubicin, as inhibition of receptor-mediated glycation stress signaling attenuated plasma-induced aortic stiffening. CONCLUSIONS: Cellular senescence and the circulating SASP milieu contribute to doxorubicin-induced aortic stiffening. Senolytics hold promise for preserving aortic stiffening following doxorubicin exposure.
- 1 October 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (10) , 1767-1777
Cellular Senescence Mediates Doxorubicin Chemotherapy-Induced Aortic Stiffening: Role of Glycation Stress
BACKGROUND: Mechanisms underlying doxorubicin chemotherapy-induced aortic stiffening are incompletely understood. To determine the role of cellular senescence and the senescence-associated secretory phenotype (SASP) in mediating doxorubicin-induced aortic stiffening and the influence of senolytic therapy. METHODS: Aortic stiffness (aortic pulse wave velocity) and associated mechanisms were assessed in young adult p16-3MR mice, a model that allows for genetic-based clearance of senescent cells with ganciclovir. Young (4–6 months) mice were injected with doxorubicin and subsequently treated with ganciclovir or the senolytic ABT263. We evaluated the influence of SASP-associated circulating factors in plasma (the circulating SASP milieu) in mediating aortic stiffening ex vivo (aortic elastic modulus) and examined the contribution of glycation stress. RESULTS: Doxorubicin increased aortic pulse wave velocity (425±6 versus control, 353±5 cm/s; P P P =0.02 versus plasma from control mice), whereas plasma from doxorubicin-ganciclovir and doxorubicin-ABT263 groups did not. Glycation stress was implicated in SASP-mediated aortic stiffening with doxorubicin, as inhibition of receptor-mediated glycation stress signaling attenuated plasma-induced aortic stiffening. CONCLUSIONS: Cellular senescence and the circulating SASP milieu contribute to doxorubicin-induced aortic stiffening. Senolytics hold promise for preserving aortic stiffening following doxorubicin exposure.
- 1 October 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (10) , 2072-2087
Cellular Senescence Contributes to Large Elastic Artery Stiffening and Endothelial Dysfunction With Aging: Amelioration With Senolytic Treatment
BACKGROUND: Here, we assessed the role of cellular senescence and the senescence associated secretory phenotype (SASP) in age-related aortic stiffening and endothelial dysfunction. METHODS: We studied young (6-8 mo) and old (27-29 mo) p16-3MR mice, which allows for genetic-based clearance of senescent cells with ganciclovir (GCV). We also treated old C57BL/6N mice with the senolytic ABT-263. RESULTS: In old mice, GCV reduced aortic stiffness assessed by aortic pulse wave velocity (PWV; 477±10 vs. 382±7 cm/s, P P =0.35); ABT-263 also reduced aortic PWV in old mice (446±9 to 356±11 cm/s, P P P =0.12) in old mice. To show an effect of the circulating SASP, we demonstrated that plasma exposure from Old-vehicle p16-3MR mice, but not from Old-GCV mice, induced aortic stiffening assessed ex vivo (elastic modulus; P P P =0.98), and EDD was higher in old C57BL/6N mice treated with ABT-263 vs. vehicle (96±1% vs. 82±3%, P P P <0.05). Circulating SASP factors related to NO signaling were associated with greater NO-mediated EDD following senescent cell clearance. CONCLUSIONS: Cellular senescence and the SASP contribute to vascular aging and senolytics hold promise for improving age-related vascular function.
- 1 October 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (10) , 2072-2087
Cellular Senescence Contributes to Large Elastic Artery Stiffening and Endothelial Dysfunction With Aging: Amelioration With Senolytic Treatment
BACKGROUND: Here, we assessed the role of cellular senescence and the senescence associated secretory phenotype (SASP) in age-related aortic stiffening and endothelial dysfunction. METHODS: We studied young (6-8 mo) and old (27-29 mo) p16-3MR mice, which allows for genetic-based clearance of senescent cells with ganciclovir (GCV). We also treated old C57BL/6N mice with the senolytic ABT-263. RESULTS: In old mice, GCV reduced aortic stiffness assessed by aortic pulse wave velocity (PWV; 477±10 vs. 382±7 cm/s, P P =0.35); ABT-263 also reduced aortic PWV in old mice (446±9 to 356±11 cm/s, P P P =0.12) in old mice. To show an effect of the circulating SASP, we demonstrated that plasma exposure from Old-vehicle p16-3MR mice, but not from Old-GCV mice, induced aortic stiffening assessed ex vivo (elastic modulus; P P P =0.98), and EDD was higher in old C57BL/6N mice treated with ABT-263 vs. vehicle (96±1% vs. 82±3%, P P P <0.05). Circulating SASP factors related to NO signaling were associated with greater NO-mediated EDD following senescent cell clearance. CONCLUSIONS: Cellular senescence and the SASP contribute to vascular aging and senolytics hold promise for improving age-related vascular function.
- 1 May 2023
- Published by American Physiological Society in Physiology
- Vol. 38 (S1)
Cellular senescence mediates doxorubicin chemotherapy-induced aortic stiffening via circulating factors
Introduction: The common chemotherapeutic agent doxorubicin (DOXO) mediates large elastic artery (aorta) stiffness in part via chronic low-grade inflammation. Cellular senescence is an established source of inflammation, largely as a result of the senescence associated secretory phenotype (SASP). Senescent cells directly contribute to aortic stiffening after DOXO administration, but the mechanistic role of the SASP in mediating DOXO-induced aortic stiffening is unknown. Purpose. To determine if aortic stiffening with DOXO is induced by changes in SASP-associated circulating factors in plasma. Methods: Young adult (6 mo) male p16-3MR mice, a model that allows for genetic clearance of cellular senescence with ganciclovir (GCV), received an intraperitoneal (IP) injection of sham (saline) or DOXO (10 mg/kg in sham). One week later, animals were treated with Vehicle (V; saline) or GCV (25 mg/kg/day in the V) via IP injection for 5 days, which resulted in 4 groups (Sham-V; Sham-GCV; DOXO-V; DOXO-GCV). Aortic stiffness was assessed in vivo via aortic pulse wave velocity (PWV) before Sham/DOXO and after V/GCV administration. Next, aorta rings from young adult (6 mo p16-3MR) male intervention naïve mice were incubated (for 48h) in standard culture media, plus the following conditions: 1) 10% fetal calf serum (FCS, control); 2) 10% Sham-V plasma; 3) 10% DOXO-V plasma; and 4) 10% DOXO-GCV plasma (n=5-7/group). Following the incubation period, aortic intrinsic mechanical wall stiffness was assessed via elastic modulus (an established ex vivo assay of aortic stiffness). Results: Aortic PWV. There was no difference in aortic PWV (cm/sec; Mean ± SEM) between the Sham-treated groups following administration of V or GCV (Sham-V, 352 ± 6; Sham-GCV, 365 ± 3; P=0.60). Mice administered with DOXO-V had higher aortic PWV (424 ± 12; P<0.0001 vs. all groups); whereas aortic PWV in the DOXO-GCV group was similar to the Sham-treated animals (345 ± 5; P=0.88 and 0.28 vs. Sham-V and Sham-GCV, respectively). Circulating SASP-induced changes in aortic elastic modulus. Plasma from the DOXO-V mice increased elastic modulus (kPa) in aorta rings from young intervention-naïve animals ~2-fold (DOXO-V, 10767 ± 765 vs FCS, 5168 ± 1199; P=0.003). Plasma from the Sham-V and DOXO-GCV mice did not influence aortic elastic modulus (Sham-V, 6426 ± 1225; DOXO-GCV, 5268 ± 517; P=0.79 and P=0.99 vs. FCS, respectively). Relation between plasma-induced changes in aortic elastic modulus and aortic PWV. Plasma-induced changes in aortic elastic modulus were significantly correlated (P=0.02; R2=0.29) with aortic PWV following V/GCV administration. Conclusion: The SASP directly contributes to the cellular senescence-associated increase in aortic stiffness after DOXO treatment. NIH K99 HL159241 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this Physiology was not involved in the peer review process.
- 1 May 2023
- Published by American Physiological Society in Physiology
- Vol. 38 (S1)
Cellular senescence mediates doxorubicin chemotherapy-induced aortic stiffening via circulating factors
Introduction: The common chemotherapeutic agent doxorubicin (DOXO) mediates large elastic artery (aorta) stiffness in part via chronic low-grade inflammation. Cellular senescence is an established source of inflammation, largely as a result of the senescence associated secretory phenotype (SASP). Senescent cells directly contribute to aortic stiffening after DOXO administration, but the mechanistic role of the SASP in mediating DOXO-induced aortic stiffening is unknown. Purpose. To determine if aortic stiffening with DOXO is induced by changes in SASP-associated circulating factors in plasma. Methods: Young adult (6 mo) male p16-3MR mice, a model that allows for genetic clearance of cellular senescence with ganciclovir (GCV), received an intraperitoneal (IP) injection of sham (saline) or DOXO (10 mg/kg in sham). One week later, animals were treated with Vehicle (V; saline) or GCV (25 mg/kg/day in the V) via IP injection for 5 days, which resulted in 4 groups (Sham-V; Sham-GCV; DOXO-V; DOXO-GCV). Aortic stiffness was assessed in vivo via aortic pulse wave velocity (PWV) before Sham/DOXO and after V/GCV administration. Next, aorta rings from young adult (6 mo p16-3MR) male intervention naïve mice were incubated (for 48h) in standard culture media, plus the following conditions: 1) 10% fetal calf serum (FCS, control); 2) 10% Sham-V plasma; 3) 10% DOXO-V plasma; and 4) 10% DOXO-GCV plasma (n=5-7/group). Following the incubation period, aortic intrinsic mechanical wall stiffness was assessed via elastic modulus (an established ex vivo assay of aortic stiffness). Results: Aortic PWV. There was no difference in aortic PWV (cm/sec; Mean ± SEM) between the Sham-treated groups following administration of V or GCV (Sham-V, 352 ± 6; Sham-GCV, 365 ± 3; P=0.60). Mice administered with DOXO-V had higher aortic PWV (424 ± 12; P<0.0001 vs. all groups); whereas aortic PWV in the DOXO-GCV group was similar to the Sham-treated animals (345 ± 5; P=0.88 and 0.28 vs. Sham-V and Sham-GCV, respectively). Circulating SASP-induced changes in aortic elastic modulus. Plasma from the DOXO-V mice increased elastic modulus (kPa) in aorta rings from young intervention-naïve animals ~2-fold (DOXO-V, 10767 ± 765 vs FCS, 5168 ± 1199; P=0.003). Plasma from the Sham-V and DOXO-GCV mice did not influence aortic elastic modulus (Sham-V, 6426 ± 1225; DOXO-GCV, 5268 ± 517; P=0.79 and P=0.99 vs. FCS, respectively). Relation between plasma-induced changes in aortic elastic modulus and aortic PWV. Plasma-induced changes in aortic elastic modulus were significantly correlated (P=0.02; R2=0.29) with aortic PWV following V/GCV administration. Conclusion: The SASP directly contributes to the cellular senescence-associated increase in aortic stiffness after DOXO treatment. NIH K99 HL159241 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this Physiology was not involved in the peer review process.
- 1 May 2023
- Published by American Physiological Society in Physiology
- Vol. 38 (S1)
Circulating factors from old mice directly induce endothelial dysfunction and aortic stiffening in young mouse arteries: A novel ex vivo experimental approach
Aging is the primary risk factor for the development of cardiovascular diseases, largely as a result of reduced arterial function, characterized by endothelial dysfunction and large elastic artery (e.g., aorta) stiffening. Changes in circulating factors (assessed in serum or plasma) may contribute to arterial dysfunction with aging; however, this has not yet been directly investigated. Heterochronic parabiosis could be used to study the influence of circulating factors from old animals on young arteries (and vice versa) but is limited by potential confounding effects of other organ systems. Thus, a highly controlled experimental model is necessary to determine the direct effects of changes in circulating factors with aging on arterial function. PURPOSE: To develop an experimental model that allows for direct assessment of circulating factors in mediating endothelial dysfunction and arterial stiffening with aging. METHODS & RESULTS: Endothelial Function. Common carotid arteries from young (3-4mo) male C57BL/6 mice were cannulated in a tissue culture pressure myograph and incubated 24h with modified Krebs buffer containing 5% serum from either young (YS; 5mo, N=4) or old (OS; 24mo, N=4) male donor mice. Endothelial function was measured as endothelium-dependent dilation (EDD) to increasing doses of acetylcholine (10-9 to 10-4M). Endothelium-independent dilation (EID) was assessed as dilation to the nitric oxide (NO) donor sodium nitroprusside (10-10 to 10-4M).Peak EDD was lower in arteries incubated with OS compared with YS (OS: 75.3±2.4%; YS: 89.4±1.3%; p=0.008). There were no differences in EID between treatments (OS: 91.7±2.5%; YS: 97.4±1.5%; p=0.06), suggesting circulating factors from old donors induced dysfunction in an endothelium-specific manner and were not attributable to changes in smooth muscle sensitivity to NO. Arterial Stiffness. Aortic rings from young (6mo) male mice were incubated 48h in standard culture media with 5% fetal bovine serum (control; N=8) or plasma from either young (YP; 6mo, N=4) or old (OP; 27mo, N=8) male donor mice and then tested for collagen elastic modulus (EM; an ex vivo measure of intrinsic mechanical wall stiffness) on an organ bath pin myograph.Collagen EM was higher (fold-difference from control) in aortic rings incubated with OP but no different in those incubated with YP (OP: 1.41±0.13, p=0.043; YP: 1.04±0.17, p=0.97), indicating higher intrinsic wall stiffness after exposure to plasma from old donors. Moreover, plasma-induced changes in aortic collagen EM were positively associated with aortic pulse wave velocity (an in vivo measure of aortic stiffness) of donor mice (r2=0.34, p=0.047), suggesting that aortic stiffening with aging is in part due to changes in circulating factors. CONCLUSIONS: These data serve as a successful demonstration of a novel ex vivo model for determining the role of circulating factors in mediating endothelial dysfunction and arterial stiffening with aging. R21 AG078408, K99 HL159241, K99/R00 HL151818. VEB & ZSC contributed equally. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this Physiology was not involved in the peer review process.
- 1 May 2023
- Published by American Physiological Society in Physiology
- Vol. 38 (S1)
Circulating factors from old mice directly induce endothelial dysfunction and aortic stiffening in young mouse arteries: A novel ex vivo experimental approach
Aging is the primary risk factor for the development of cardiovascular diseases, largely as a result of reduced arterial function, characterized by endothelial dysfunction and large elastic artery (e.g., aorta) stiffening. Changes in circulating factors (assessed in serum or plasma) may contribute to arterial dysfunction with aging; however, this has not yet been directly investigated. Heterochronic parabiosis could be used to study the influence of circulating factors from old animals on young arteries (and vice versa) but is limited by potential confounding effects of other organ systems. Thus, a highly controlled experimental model is necessary to determine the direct effects of changes in circulating factors with aging on arterial function. PURPOSE: To develop an experimental model that allows for direct assessment of circulating factors in mediating endothelial dysfunction and arterial stiffening with aging. METHODS & RESULTS: Endothelial Function. Common carotid arteries from young (3-4mo) male C57BL/6 mice were cannulated in a tissue culture pressure myograph and incubated 24h with modified Krebs buffer containing 5% serum from either young (YS; 5mo, N=4) or old (OS; 24mo, N=4) male donor mice. Endothelial function was measured as endothelium-dependent dilation (EDD) to increasing doses of acetylcholine (10-9 to 10-4M). Endothelium-independent dilation (EID) was assessed as dilation to the nitric oxide (NO) donor sodium nitroprusside (10-10 to 10-4M).Peak EDD was lower in arteries incubated with OS compared with YS (OS: 75.3±2.4%; YS: 89.4±1.3%; p=0.008). There were no differences in EID between treatments (OS: 91.7±2.5%; YS: 97.4±1.5%; p=0.06), suggesting circulating factors from old donors induced dysfunction in an endothelium-specific manner and were not attributable to changes in smooth muscle sensitivity to NO. Arterial Stiffness. Aortic rings from young (6mo) male mice were incubated 48h in standard culture media with 5% fetal bovine serum (control; N=8) or plasma from either young (YP; 6mo, N=4) or old (OP; 27mo, N=8) male donor mice and then tested for collagen elastic modulus (EM; an ex vivo measure of intrinsic mechanical wall stiffness) on an organ bath pin myograph.Collagen EM was higher (fold-difference from control) in aortic rings incubated with OP but no different in those incubated with YP (OP: 1.41±0.13, p=0.043; YP: 1.04±0.17, p=0.97), indicating higher intrinsic wall stiffness after exposure to plasma from old donors. Moreover, plasma-induced changes in aortic collagen EM were positively associated with aortic pulse wave velocity (an in vivo measure of aortic stiffness) of donor mice (r2=0.34, p=0.047), suggesting that aortic stiffening with aging is in part due to changes in circulating factors. CONCLUSIONS: These data serve as a successful demonstration of a novel ex vivo model for determining the role of circulating factors in mediating endothelial dysfunction and arterial stiffening with aging. R21 AG078408, K99 HL159241, K99/R00 HL151818. VEB & ZSC contributed equally. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this Physiology was not involved in the peer review process.
- 13 October 2022
- Published by Wiley in The Journal of Physiology
- Vol. 600 (21) , 4633-4651
Initiation of 3,3‐dimethyl‐1‐butanol at midlife prevents endothelial dysfunction and attenuates in vivo aortic stiffening with ageing in mice
Vascular dysfunction: develops progressively with ageing; increases the risk of cardiovascular diseases (CVD); and is characterized by endothelial dysfunction and arterial stiffening, which are primarily mediated by superoxide‐driven oxidative stress and consequently reduced nitric oxide (NO) bioavailability and arterial structural changes. Interventions initiated before vascular dysfunction manifests may have more promise for reducing CVD risk than interventions targeting established dysfunction. Gut microbiome‐derived trimethylamine N‐oxide (TMAO) induces vascular dysfunction, is associated with higher CV risk, and can be suppressed by 3,3‐dimethyl‐1‐butanol (DMB). We investigated whether DMB supplementation could prevent age‐related vascular dysfunction in C57BL/6N mice when initiated prior to development of dysfunction. Mice received drinking water with 1% DMB or normal drinking water (control) from midlife (18 months) until being studied at 21, 24 or 27 months of age, and were compared to young adult (5 month) mice. Endothelial function [carotid artery endothelium‐dependent dilatation (EDD) to acetylcholine; pressure myography] progressively declined with age in control mice, which was fully prevented by DMB via higher NO‐mediated EDD and lower superoxide‐related suppression of EDD (normalization of EDD with the superoxide dismutase mimetic TEMPOL). In vivo aortic stiffness (pulse wave velocity) increased progressively with age in controls, but DMB attenuated stiffening by ∼ 70%, probably due to preservation of endothelial function, as DMB did not affect aortic intrinsic mechanical (structural) stiffness (stress–strain testing) nor adventitial abundance of the arterial structural protein collagen. Our findings indicate that long‐term DMB supplementation prevents/attenuates age‐related vascular dysfunction, and therefore has potential for translation to humans for reducing CV risk with ageing. image Key points: Vascular dysfunction, characterized by endothelial dysfunction and arterial stiffening, develops progressively with ageing and increases the risk of cardiovascular diseases (CVD). Interventions aimed at preventing the development of CV risk factors have more potential for preventing CVD relative to those aimed at reversing established dysfunction. The gut microbiome‐derived metabolite trimethylamine N‐oxide (TMAO) induces vascular dysfunction, is associated with higher CV risk and can be suppressed by supplementation with 3,3‐dimethyl‐1‐butanol (DMB). In mice, DMB prevented the development of endothelial dysfunction and delayed and attenuated in vivo arterial stiffening with ageing when supplementation was initiated in midlife, prior to the development of dysfunction. DMB supplementation or other TMAO‐suppressing interventions have potential for translation to humans for reducing CV risk with ageing.
- 13 October 2022
- Published by Wiley in The Journal of Physiology
- Vol. 600 (21) , 4633-4651
Initiation of 3,3‐dimethyl‐1‐butanol at midlife prevents endothelial dysfunction and attenuates in vivo aortic stiffening with ageing in mice
Vascular dysfunction: develops progressively with ageing; increases the risk of cardiovascular diseases (CVD); and is characterized by endothelial dysfunction and arterial stiffening, which are primarily mediated by superoxide‐driven oxidative stress and consequently reduced nitric oxide (NO) bioavailability and arterial structural changes. Interventions initiated before vascular dysfunction manifests may have more promise for reducing CVD risk than interventions targeting established dysfunction. Gut microbiome‐derived trimethylamine N‐oxide (TMAO) induces vascular dysfunction, is associated with higher CV risk, and can be suppressed by 3,3‐dimethyl‐1‐butanol (DMB). We investigated whether DMB supplementation could prevent age‐related vascular dysfunction in C57BL/6N mice when initiated prior to development of dysfunction. Mice received drinking water with 1% DMB or normal drinking water (control) from midlife (18 months) until being studied at 21, 24 or 27 months of age, and were compared to young adult (5 month) mice. Endothelial function [carotid artery endothelium‐dependent dilatation (EDD) to acetylcholine; pressure myography] progressively declined with age in control mice, which was fully prevented by DMB via higher NO‐mediated EDD and lower superoxide‐related suppression of EDD (normalization of EDD with the superoxide dismutase mimetic TEMPOL). In vivo aortic stiffness (pulse wave velocity) increased progressively with age in controls, but DMB attenuated stiffening by ∼ 70%, probably due to preservation of endothelial function, as DMB did not affect aortic intrinsic mechanical (structural) stiffness (stress–strain testing) nor adventitial abundance of the arterial structural protein collagen. Our findings indicate that long‐term DMB supplementation prevents/attenuates age‐related vascular dysfunction, and therefore has potential for translation to humans for reducing CV risk with ageing. image Key points: Vascular dysfunction, characterized by endothelial dysfunction and arterial stiffening, develops progressively with ageing and increases the risk of cardiovascular diseases (CVD). Interventions aimed at preventing the development of CV risk factors have more potential for preventing CVD relative to those aimed at reversing established dysfunction. The gut microbiome‐derived metabolite trimethylamine N‐oxide (TMAO) induces vascular dysfunction, is associated with higher CV risk and can be suppressed by supplementation with 3,3‐dimethyl‐1‐butanol (DMB). In mice, DMB prevented the development of endothelial dysfunction and delayed and attenuated in vivo arterial stiffening with ageing when supplementation was initiated in midlife, prior to the development of dysfunction. DMB supplementation or other TMAO‐suppressing interventions have potential for translation to humans for reducing CV risk with ageing.
- 11 June 2021
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 321 (1) , H185-H196
Apigenin restores endothelial function by ameliorating oxidative stress, reverses aortic stiffening, and mitigates vascular inflammation with aging
We assessed the efficacy of oral supplementation with the flavanoid apigenin on arterial function during aging and identified critical mechanisms of action. Young (6 mo) and old (27 mo) C57BL/6N mice (model of arterial aging) consumed drinking water containing vehicle (0.2% carboxymethylcellulose; 10 young and 7 old) or apigenin (0.5 mg/mL in vehicle; 10 young and 9 old) for 6 wk. In vehicle-treated animals, isolated carotid artery endothelium-dependent dilation (EDD), bioassay of endothelial function, was impaired in old versus young (70% ± 9% vs. 92% ± 1%, P < 0.0001) due to reduced nitric oxide (NO) bioavailability. Old mice had greater arterial reactive oxygen species (ROS) production and oxidative stress (higher nitrotyrosine) associated with greater nicotinamide adenine dinucleotide phosphate oxidase (oxidant enzyme) and lower superoxide dismutase 1 and 2 (antioxidant enzymes); ex vivo administration of Tempol (antioxidant) restored EDD to young levels, indicating ROS-mediated suppression of EDD. Old animals also had greater aortic stiffness as indicated by higher aortic pulse wave velocity (PWV, 434 ± 9 vs. 346 ± 5 cm/s, P < 0.0001) due to greater intrinsic aortic wall stiffness associated with lower elastin levels and higher collagen, advanced glycation end products (AGEs), and proinflammatory cytokine abundance. In old mice, apigenin restored EDD (96% ± 2%) by increasing NO bioavailability, normalized arterial ROS, oxidative stress, and antioxidant expression, and abolished ROS inhibition of EDD. Moreover, apigenin prevented foam cell formation in vitro (initiating step in atherosclerosis) and mitigated age-associated aortic stiffening (PWV 373 ± 5 cm/s) by normalizing aortic intrinsic wall stiffness, collagen, elastin, AGEs, and inflammation. Thus, apigenin is a promising therapeutic for arterial aging. NEW & NOTEWORTHY Our study provides novel evidence that oral apigenin supplementation can reverse two clinically important indicators of arterial dysfunction with age, namely, vascular endothelial dysfunction and large elastic artery stiffening, and prevents foam cell formation in an established cell culture model of early atherosclerosis. Importantly, our results provide extensive insight into the biological mechanisms of apigenin action, including increased nitric oxide bioavailability, normalization of age-related increases in arterial ROS production and oxidative stress, reversal of age-associated aortic intrinsic mechanical wall stiffening and adverse remodeling of the extracellular matrix, and suppression of vascular inflammation. Given that apigenin is commercially available as a dietary supplement in humans, these preclinical findings provide the experimental basis for future translational studies assessing the potential of apigenin to treat arterial dysfunction and reduce cardiovascular disease risk with aging.
- 11 June 2021
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 321 (1) , H185-H196
Apigenin restores endothelial function by ameliorating oxidative stress, reverses aortic stiffening, and mitigates vascular inflammation with aging
We assessed the efficacy of oral supplementation with the flavanoid apigenin on arterial function during aging and identified critical mechanisms of action. Young (6 mo) and old (27 mo) C57BL/6N mice (model of arterial aging) consumed drinking water containing vehicle (0.2% carboxymethylcellulose; 10 young and 7 old) or apigenin (0.5 mg/mL in vehicle; 10 young and 9 old) for 6 wk. In vehicle-treated animals, isolated carotid artery endothelium-dependent dilation (EDD), bioassay of endothelial function, was impaired in old versus young (70% ± 9% vs. 92% ± 1%, P < 0.0001) due to reduced nitric oxide (NO) bioavailability. Old mice had greater arterial reactive oxygen species (ROS) production and oxidative stress (higher nitrotyrosine) associated with greater nicotinamide adenine dinucleotide phosphate oxidase (oxidant enzyme) and lower superoxide dismutase 1 and 2 (antioxidant enzymes); ex vivo administration of Tempol (antioxidant) restored EDD to young levels, indicating ROS-mediated suppression of EDD. Old animals also had greater aortic stiffness as indicated by higher aortic pulse wave velocity (PWV, 434 ± 9 vs. 346 ± 5 cm/s, P < 0.0001) due to greater intrinsic aortic wall stiffness associated with lower elastin levels and higher collagen, advanced glycation end products (AGEs), and proinflammatory cytokine abundance. In old mice, apigenin restored EDD (96% ± 2%) by increasing NO bioavailability, normalized arterial ROS, oxidative stress, and antioxidant expression, and abolished ROS inhibition of EDD. Moreover, apigenin prevented foam cell formation in vitro (initiating step in atherosclerosis) and mitigated age-associated aortic stiffening (PWV 373 ± 5 cm/s) by normalizing aortic intrinsic wall stiffness, collagen, elastin, AGEs, and inflammation. Thus, apigenin is a promising therapeutic for arterial aging. NEW & NOTEWORTHY Our study provides novel evidence that oral apigenin supplementation can reverse two clinically important indicators of arterial dysfunction with age, namely, vascular endothelial dysfunction and large elastic artery stiffening, and prevents foam cell formation in an established cell culture model of early atherosclerosis. Importantly, our results provide extensive insight into the biological mechanisms of apigenin action, including increased nitric oxide bioavailability, normalization of age-related increases in arterial ROS production and oxidative stress, reversal of age-associated aortic intrinsic mechanical wall stiffening and adverse remodeling of the extracellular matrix, and suppression of vascular inflammation. Given that apigenin is commercially available as a dietary supplement in humans, these preclinical findings provide the experimental basis for future translational studies assessing the potential of apigenin to treat arterial dysfunction and reduce cardiovascular disease risk with aging.
- 10 May 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 78 (2) , 499-511
Gut Microbiome-Derived Metabolite Trimethylamine N-Oxide Induces Aortic Stiffening and Increases Systolic Blood Pressure With Aging in Mice and Humans
Aging is associated with stiffening of the large elastic arteries and consequent increases in systolic blood pressure (SBP), which together increase cardiovascular disease risk; however, the upstream mechanisms are incompletely understood. Using complementary translational approaches in mice and humans, we investigated the role of the gut microbiome-derived metabolite trimethylamine N-oxide (TMAO) in age-related aortic stiffening and increased SBP. Aortic stiffness was measured using carotid-femoral or aortic pulse wave velocity (PWV) in humans and mice, respectively. Study 1: Plasma TMAO concentrations were elevated ( P r 2 =0.15, P r 2 =0.09, P <0.001), independent of traditional cardiovascular risk factors. Study 2: Dietary supplementation with TMAO increased aPWV in young mice and exacerbated the already elevated aPWV of old mice, accompanied by increases in SBP of ≈10 mm Hg in both groups. TMAO-supplemented versus control-fed mice also had higher intrinsic mechanical stiffness of the aorta (stress-strain testing) associated with higher aortic abundance of advanced glycation end-products, which form crosslinks between structural proteins to promote aortic stiffening. Study 3: Ex vivo incubation of aortic rings with TMAO increased intrinsic stiffness, which was attenuated by the advanced glycation end-products crosslink breaker alagebrium and prevented by inhibition of superoxide signaling. TMAO induces aortic stiffening and increases SBP via formation of advanced glycation end-products and superoxide-stimulated oxidative stress, which together increase intrinsic wall stiffness. Increases in circulating TMAO with aging represent a novel therapeutic target for reducing risk of aortic stiffening-related clinical disorders.
- 10 May 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 78 (2) , 499-511
Gut Microbiome-Derived Metabolite Trimethylamine N-Oxide Induces Aortic Stiffening and Increases Systolic Blood Pressure With Aging in Mice and Humans
Aging is associated with stiffening of the large elastic arteries and consequent increases in systolic blood pressure (SBP), which together increase cardiovascular disease risk; however, the upstream mechanisms are incompletely understood. Using complementary translational approaches in mice and humans, we investigated the role of the gut microbiome-derived metabolite trimethylamine N-oxide (TMAO) in age-related aortic stiffening and increased SBP. Aortic stiffness was measured using carotid-femoral or aortic pulse wave velocity (PWV) in humans and mice, respectively. Study 1: Plasma TMAO concentrations were elevated ( P r 2 =0.15, P r 2 =0.09, P <0.001), independent of traditional cardiovascular risk factors. Study 2: Dietary supplementation with TMAO increased aPWV in young mice and exacerbated the already elevated aPWV of old mice, accompanied by increases in SBP of ≈10 mm Hg in both groups. TMAO-supplemented versus control-fed mice also had higher intrinsic mechanical stiffness of the aorta (stress-strain testing) associated with higher aortic abundance of advanced glycation end-products, which form crosslinks between structural proteins to promote aortic stiffening. Study 3: Ex vivo incubation of aortic rings with TMAO increased intrinsic stiffness, which was attenuated by the advanced glycation end-products crosslink breaker alagebrium and prevented by inhibition of superoxide signaling. TMAO induces aortic stiffening and increases SBP via formation of advanced glycation end-products and superoxide-stimulated oxidative stress, which together increase intrinsic wall stiffness. Increases in circulating TMAO with aging represent a novel therapeutic target for reducing risk of aortic stiffening-related clinical disorders.
- 15 March 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 77 (5) , 1581-1590
Tumor Necrosis Factor Alpha-Mediated Inflammation and Remodeling of the Extracellular Matrix Underlies Aortic Stiffening Induced by the Common Chemotherapeutic Agent Doxorubicin
Aortic stiffening is a major independent risk factor for cardiovascular diseases, kidney dysfunction, and cognitive impairment. Doxorubicin chemotherapy-treated cancer survivors have greater aortic stiffness relative to healthy controls, but the mechanisms by which doxorubicin induces arterial stiffening are unknown. We tested the hypothesis that doxorubicin increases aortic stiffness by increasing intrinsic mechanical wall stiffness due to proinflammatory signaling-induced adverse structural changes, including collagen deposition (fibrosis), elastin fragmentation, and formation of AGEs (advanced glycation end products). In vivo aortic stiffness (assessed via aortic pulse wave velocity), aortic intrinsic wall stiffness (ex vivo assessment of elastic modulus), and potential underlying mechanisms were assessed 4 weeks after administration of doxorubicin (10 mg/kg) or vehicle (saline) in young adult male C57BL6/J mice. Aortic pulse wave velocity increased by ~30% following doxorubicin (pre: 341±18 versus post: 431±28 cm/s, mean±SEM, P =0.001) and aortic elastic modulus was ~100% higher following doxorubicin (5438±445 kPa) versus vehicle (2659±433 kPa; P =0.003). These effects of doxorubicin were associated with an ~3-fold greater formation of AGEs ( P =0.01) and an ~50% reduction in elastin ( P =0.01), whereas collagen deposition was unaffected. Doxorubicin increased aortic proinflammatory cytokines ( P =0.03) without a compensatory increase in the anti-inflammatory cytokine interleukin-10. Direct ex vivo exposure of aorta rings to doxorubicin mimicked the increase in aortic elastic modulus observed in vivo with doxorubicin, whereas TNF-α (tumor necrosis factor-α) inhibition prevented this response. Doxorubicin induces aortic stiffening in vivo due, in part, to an increase in intrinsic wall stiffness associated with elastin degradation and AGEs formation and mediated by TNF-α-dependent vascular inflammation.
- 15 March 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 77 (5) , 1581-1590
Tumor Necrosis Factor Alpha-Mediated Inflammation and Remodeling of the Extracellular Matrix Underlies Aortic Stiffening Induced by the Common Chemotherapeutic Agent Doxorubicin
Aortic stiffening is a major independent risk factor for cardiovascular diseases, kidney dysfunction, and cognitive impairment. Doxorubicin chemotherapy-treated cancer survivors have greater aortic stiffness relative to healthy controls, but the mechanisms by which doxorubicin induces arterial stiffening are unknown. We tested the hypothesis that doxorubicin increases aortic stiffness by increasing intrinsic mechanical wall stiffness due to proinflammatory signaling-induced adverse structural changes, including collagen deposition (fibrosis), elastin fragmentation, and formation of AGEs (advanced glycation end products). In vivo aortic stiffness (assessed via aortic pulse wave velocity), aortic intrinsic wall stiffness (ex vivo assessment of elastic modulus), and potential underlying mechanisms were assessed 4 weeks after administration of doxorubicin (10 mg/kg) or vehicle (saline) in young adult male C57BL6/J mice. Aortic pulse wave velocity increased by ~30% following doxorubicin (pre: 341±18 versus post: 431±28 cm/s, mean±SEM, P =0.001) and aortic elastic modulus was ~100% higher following doxorubicin (5438±445 kPa) versus vehicle (2659±433 kPa; P =0.003). These effects of doxorubicin were associated with an ~3-fold greater formation of AGEs ( P =0.01) and an ~50% reduction in elastin ( P =0.01), whereas collagen deposition was unaffected. Doxorubicin increased aortic proinflammatory cytokines ( P =0.03) without a compensatory increase in the anti-inflammatory cytokine interleukin-10. Direct ex vivo exposure of aorta rings to doxorubicin mimicked the increase in aortic elastic modulus observed in vivo with doxorubicin, whereas TNF-α (tumor necrosis factor-α) inhibition prevented this response. Doxorubicin induces aortic stiffening in vivo due, in part, to an increase in intrinsic wall stiffness associated with elastin degradation and AGEs formation and mediated by TNF-α-dependent vascular inflammation.
- Open Access
- 25 July 2019
- Published by Wiley in The Journal of Physiology
- Vol. 597 (16) , 4137-4138
Physical activity‐related suppression of cancer growth: is a transient increase in cytokine production required for tumour angiogenesis?
- 25 July 2019
- Published by Wiley in The Journal of Physiology
- Vol. 597 (16) , 4137-4138
Open AccessPhysical activity‐related suppression of cancer growth: is a transient increase in cytokine production required for tumour angiogenesis?